Chemed Corp. (CHE)

NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$512.98-1.38%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Chemed Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	705.34M
EPS	—	7.375
FY 2026 · Annual
Revenue	—	2.72B
EPS	$23.25–$24.25non-GAAP	25.494
Revenue growth	3%–3.5%	—
FY 2027 · Annual
Revenue	—	2.89B
EPS	—	27.518

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS growth and guidance	EPS guidance for 2026 is raised to about $24.40 per share.	Intact	EPS guidance falls below $24.00 for FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management raised full-year 2026 EPS guidance midpoint from $24.375 in 2026-Q1 to $25.375 in 2026-Q2, reflecting VITAS outperformance and share repurchases. This represents a 17.8% increase over 2025 adjusted EPS of $21.55. The trajectory matches management's stated intent to increase EPS guidance. Delivery assessment Oct 24, 2026
Revenue growth excluding Medicare Cap	Chemed grows revenue about 7% a year excluding Medicare Cap.	Intact	YoY revenue growth excluding Medicare Cap falls below 6.5% in FY26	Revenue growth: 8.8% FY2026-Q2; GAAP. Published target: 6.5% to 7.5% annual growth excluding Medicare Cap. Target period is not explicitly aligned with this observation. Source published Jul 31, 20268.799802 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 8b9d9d7a-3f4b-4b63-bfbd-8ea7167ce98b. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. VITAS revenue grew from approximately $396M in 2025-Q2 to $443.3M in 2026-Q2 (+11.9%), with admissions rising 9.0% in the same period. Management has consistently emphasized returning to normal growth post-Medicare Cap, and the trajectory is delivering with accelerating revenue and admissions growth. Delivery assessment Oct 24, 2026
Roto-Rooter EBITDA margin	A supporting condition in Chemed Corp.'s published investment case. The stated target is Maintain EBITDA margin within targeted range.	Intact	EBITDA margin falls significantly below targeted range in FY26	EBITDA margin: 15.06% FY2026-Q2; GAAP. Published target: Maintain EBITDA margin within targeted range. Target percentage unit is not explicit. Source published Jul 31, 202615.063624 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Roto-Rooter adjusted EBITDA margin declined from 22.5% in 2025-Q1 to 21.1% in 2026-Q2, reflecting headwinds and elevated marketing costs. Management lowered full-year 2026 margin guidance slightly to 21.5%-22.5%. The trajectory shows mixed delivery with margin pressure but ongoing focus on margin maintenance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 3
2026-07-25	Unavailable	Unavailable	4 / 4
2026-07-26	Unavailable	Unavailable	4 / 4
2026-07-27	Unavailable	Unavailable	4 / 4
2026-07-28	Unavailable	Unavailable	4 / 4
2026-07-29	Unavailable	Unavailable	4 / 4
2026-07-30	Unavailable	Unavailable	4 / 4
2026-07-31	Unavailable	Unavailable	2 / 3
2026-08-01	Unavailable	Unavailable	4 / 4
2026-08-02	Unavailable	Unavailable	4 / 4
2026-08-03	Unavailable	Unavailable	2 / 3
2026-08-04	Unavailable	Unavailable	2 / 3
2026-08-05	Unavailable	Unavailable	2 / 3
2026-08-06	Unavailable	Unavailable	4 / 4
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	Unavailable	4 / 4
2026-08-09	Unavailable	Unavailable	4 / 4
2026-08-10	Unavailable	Unavailable	4 / 4
2026-08-11	Unavailable	Unavailable	4 / 4
2026-08-12	Unavailable	Unavailable	4 / 4
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 3
2026-08-21	Unavailable	Unavailable	2 / 3
2026-08-22	Unavailable	Unavailable	2 / 3
2026-08-23	Unavailable	Unavailable	2 / 3
2026-08-24	Unavailable	Unavailable	2 / 3
2026-08-25	Unavailable	Unavailable	2 / 3
2026-08-26	Unavailable	Unavailable	2 / 3
2026-08-27	Unavailable	Unavailable	2 / 3
2026-08-28	Unavailable	Unavailable	2 / 3
2026-08-29	Unavailable	Unavailable	2 / 3
2026-08-30	Unavailable	Unavailable	2 / 3
2026-08-31	Unavailable	Unavailable	2 / 3
2026-09-01	Unavailable	Unavailable	2 / 3
2026-09-02	Unavailable	Unavailable	2 / 3
2026-09-03	Unavailable	Unavailable	2 / 3
2026-09-04	Unavailable	Unavailable	2 / 3
2026-09-05	Unavailable	Unavailable	2 / 3
2026-09-06	Unavailable	Unavailable	2 / 3
2026-09-07	Unavailable	Unavailable	2 / 3
2026-09-08	Unavailable	Unavailable	2 / 3
2026-09-09	Unavailable	Unavailable	2 / 3
2026-09-10	Unavailable	Unavailable	2 / 3
2026-09-11	Unavailable	Unavailable	2 / 3
2026-09-12	Unavailable	Unavailable	2 / 3
2026-09-13	Unavailable	Unavailable	2 / 3
2026-09-14	Unavailable	Unavailable	2 / 3
2026-09-15	Unavailable	Unavailable	2 / 3
2026-09-16	Unavailable	Unavailable	2 / 3
2026-09-17	Unavailable	Unavailable	2 / 3
2026-09-18	Unavailable	Unavailable	2 / 3
2026-09-19	Unavailable	Unavailable	2 / 3
2026-09-20	Unavailable	Unavailable	2 / 3
2026-09-21	Unavailable	Unavailable	2 / 3
2026-09-22	Unavailable	Unavailable	2 / 3
2026-09-23	Unavailable	Unavailable	2 / 3
2026-09-24	Unavailable	Unavailable	2 / 3
2026-09-25	Unavailable	Unavailable	2 / 3
2026-09-26	Unavailable	Unavailable	3 / 3
2026-09-27	Unavailable	Unavailable	3 / 3
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	1	3
2026-06-01	1	3
2026-07-01	1	3
2026-08-01	1	3
2026-09-01	2	3
2026-10-01	2	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 2 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSSep 25

$650.00New observation · no comparable prior

$0$357.50$715.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS growth and guidanceDirect metric needs a verified mapping
Revenue growth excluding Medicare CapRevenue growth: 8.8%
Roto-Rooter EBITDA marginEBITDA margin: 15.06%

Next proof point

Oct 27, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.8%Typical daily move · historical

Downside history

-23.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Chemed Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

CHE is a service business with a mix of steadier healthcare demand and more cyclical home-service activity. Its long-term thesis is intact: recent financial performance is strong, management is stable, and VITAS growth is on track, though Roto-Rooter margin delivery is behind.

What's priced into Chemed Corp.

The valuation is characterized as cheap versus peers, with a small expectations gap and no flagged signs of fragile pricing. The evidence suggests the market is not assuming a large amount of further improvement, but the valuation model has high confidence and the overall value assessment is neutral.

What the fundamentals likely do

Near term, VITAS revenue and admissions growth support the raised 2026 earnings guidance, while Roto-Rooter faces margin pressure and higher marketing costs. Recent earnings beats and a stronger healthcare sector backdrop are supportive, but prior misses and the possibility of guidance being cut after a raise remain risks.

What Chemed Corp. hinges on

The multi-year view depends on VITAS sustaining growth and management delivering on its raised earnings outlook. Roto-Rooter margin recovery is a swing factor, as are a weakening jobs trend and healthcare-sector results from bellwethers such as HCA, THC, and EHC.